The VC fund is setting up the venture with its CSO, David Grainger, Ph.D., and Johnson & Johnson’s Richard Mason.
The new funding will propel Unity Biotechnologies' osteoarthritis asset into its first clinical trial.
The short seller launched the assault after seeing shares in Proteostasis rise 200% in three months.
ShangPharma Innovation is growing its life science incubator on the West Coast as it looks to help early-stage biomedical work get off the ground.
Artificial intelligence company twoXAR says first-round financing will also help it build its pipeline and recruit new staff.
The IPO will equip Alzheon to take its reworking of a once-failed beta amyloid drug into a pivotal trial in a subset of Alzheimer’s patients.
Arbor Biotechnologies has emerged from the shadows with $15.6 million in funding and a CRISPR enzyme that targets RNA.
Ideaya expects to get its first synthetic lethality and immuno-oncology assets into human testing in the first half of next year.
Foghorn seeks to unravel chromatin regulation and develop drugs to correct problems with it.
Perceptive leads a Series B round that will fund Crinetics' CRN00808 candidate through proof-of-concept studies.